Uncategorized Archives - Page 7 of 165

ThursdayJul 23, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific…

WednesdayJul 22, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program. The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting. VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered…

TuesdayJul 21, 2026 11:15 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change…

TuesdayJul 21, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent. Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging. A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results showing a…

MondayJul 20, 2026 9:45 am

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Earth Science Tech, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, is distinct from other OTC listed companies based on its record of strong results, hard real estate assets, vertical integration, and robust corporate structure The company has reported year-over-year growth in revenue and gross profits since fiscal year 2024, progress attributable to careful strategic and complementary investments and acquisitions, which have not added debt to its balance sheet Its acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate and owns property that houses ETST’s Texas pharmacy Investopedia lists the lack of reliable…

WednesdayJul 15, 2026 9:00 am

Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position

Earth Science Tech has positioned itself within the rapidly evolving telehealth industry, through its investments into subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc. The company is capitalizing on the surging demand and clinical effectiveness of peptide therapies, an industry expected to hit $249 billion by 2033. ETST’s success has been built on its proprietary tech and IT infrastructure, a significant competitive edge, and continues to push innovative tech development and expand vertical integration. Earth Science Tech (OTC: ETST), a strategic holding company building value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services,…

TuesdayJul 14, 2026 10:00 am

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

Not many people know that respiratory infections have been strongly linked to cardiovascular disease events, and this knowledge gap is leading to missed opportunities to use readily accessible vaccines to limit the severity and challenges arising from cardiovascular disease. Professor Colin Russell, based at the School of Medicine at Amsterdam University, explains why it is important to understand the role that respiratory infections play in cardiovascular disease. He points out that fragmented data on immunization coverage is a leading barrier that prevents vaccination against respiratory infections from making a bigger contribution in the fight against cardiovascular disease. Prof. Russell points…

TuesdayJul 14, 2026 9:45 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks. VERAXA's Boolean "AND-gated" BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because…

FridayJul 10, 2026 10:00 am

New Vaccine Gives Brain Cancer Patients Hope of Longer Survival

Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors. In a study that was published in the Nature journal, the scientists described their small trial that involved 33 patients diagnosed with high-grade astrocytomas. These tumors usually recur and progress to a level that…

ThursdayJul 09, 2026 10:00 am

Understanding Why Treatment Resistance Exists in Many Cancers

One of the biggest challenges that the medical community faces in fighting cancer is the treatment resistance phenomenon. Treatment resistance results in poor prognosis for patients due to the inability of available treatments to deliver meaningful beneficial changes in cancer progression. We discuss some of the mechanisms that have been studied as scientists search for a solution to treatment resistance in cancer patients. For starters, it has now become clear that treatment resistance can be broadly categorized into two distinct groups. The first is primary/innate/intrinsic resistance, in which from the get-go, a patient doesn’t respond to the available cancer treatments…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal

Earth Science Tech Inc. (ETST) Continues to Optimize Operational and Financial Frameworks to Maintain Its Singular Position of Strength

Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

New Vaccine Gives Brain Cancer Patients Hope of Longer Survival

Understanding Why Treatment Resistance Exists in Many Cancers

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search